Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

International Journal of Clinical Oncology

Volumn 15, Issue 5, 2010, Pages 468-471

  Watanabe, Yoh ^a   Etoh, Tomomaro ^a   Koike, Eiji ^a   Mizuno, Yoshiaki ^a   Wang, Wei Min ^a   Hoshiai, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclophosphamide; Recurrent ovarian cancer; Salvage therapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; JAPAN; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149360957     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0094-1     Document Type: Article

References (23)

1. Pujade-Lauraine S, Mahner S, Kaern J et al (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CARYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27:18s (suppl; abstr LBA5509)
2. AJ Gonzalez-Martin E Calvo I Bover, et al. 2005 Randomized phase II trial of carboplatin versus paclitaxel carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Onvestigation en Cancer de Ovario) study Ann Oncol 16 749 755 1:STN:280:DC%2BD2M3gvValtA%3D%3D 10.1093/annonc/mdi147 15817604 (Pubitemid 40767095)
3. MK Parmer JA Ledermann N Colombo, et al. 2003 Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2099 2106 10.1016/S0140-6736(03)13718-X (Pubitemid 36782252)
4. DG Mutch M Orlando T Goss, et al. 2007 Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2811 2818 1:CAS:528: DC%2BD2sXosValtbs%3D 10.1200/JCO.2006.09.6735 17602086 (Pubitemid 47123191)
5. W ten Bokkel Huinink SR Lane GA Ross 2004 Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma Ann Oncol 15 100 103 1:STN:280:DC%2BD3srps1KmtQ%3D%3D 10.1093/annonc/mdh025 14679127 (Pubitemid 38139610)
6. AN Gordon JT Fleagle D Guthrie, et al. 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322 1:CAS:528:DC%2BD3MXlvVamsr8%3D 11454878
7. Y Watanabe E Koike H Nakai, et al. 2008 Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer Int J Clin Oncol 13 345 348 1:CAS:528:DC%2BD1cXhtFGgsLjK 10.1007/s10147-008-0765-3 18704636
8. National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology-v.2.2009. http://www.nccn.org/professionals/physician-gls/PDF/ovarain. pdf
9. Southwest Oncology Group Statistical Center. http://www.swogstat.org/ stat/public/one-binomial.htm
10. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov
12. Japan Society of Gynecologic Oncology Ovarian cancer treatment guidelines 2007 (in Japanese). KANEHARA & Co., Ltd., Tokyo
13. J Sehouli D Stengel G Oskay-Oezcelik, et al. 2008 Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 26 3176 3182 1:CAS:528: DC%2BD1cXptlKgtLg%3D 10.1200/JCO.2007.15.1258 18591555
14. G Ferrandina M Ludovici D Lorusso, et al. 2008 Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 890 896 1:CAS:528:DC%2BD1cXjtFelsbY%3D 10.1200/JCO.2007.13.6606 18281662 (Pubitemid 351398081)
15. AN Gordon M Tonda S Sun, et al. 2004 Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 1 8 1:CAS:528:DC%2BD2cXnvVOisrg%3D 10.1016/j.ygyno.2004.07.011 15385103 (Pubitemid 39286270)
16. S Alici P Saip Y Eralp, et al. 2003 Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC) Am J Clin Oncol 26 358 362 1:CAS:528:DC%2BD2cXmt1Shsw%3D%3D 10.1097/00000421-200308000-00010 12902885 (Pubitemid 36962077)
17. PG Rose JA Blessing AR Mayer, et al. 1998 Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 16 405 410 1:CAS:528:DyaK1cXhtFSht7s%3D 9469322
18. R de Wit M van der Burg A Gaast, et al. 1994 Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy Ann Oncol 5 656 657 7993845
19. MT Saymour JL Mansi CJ Gallagher, et al. 1994 Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease Br J Cancer 69 191 195
20. G Omura JA Blessing CE Ehrlich, et al. 1986 A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study Cancer 57 1725 1730 1:STN:280:DyaL287mtFeksg%3D%3D 10.1002/1097-0142(19860501)57:9<1725::AID- CNCR2820570903>3.0.CO;2-J 3513943
21. RJ Weat SF Zweig 1997 Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide Eur J Gyneacol Oncol 18 343 348
22. MJ Piccart K Bertelsen K James, et al. 2000 Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 699 708 1:CAS:528:DC%2BD3cXjslSns7c%3D 10.1093/jnci/92.9.699 10793106
23. WP McGuire WJ Hoskins MF Brady, et al. 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 6 1:CAS:528:DyaK28XhtFKiur4%3D 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)